The state-of-the-art in predictive toxicogenomics.
Curr Opin Drug Discov Devel
; 9(1): 84-91, 2006 Jan.
Article
em En
| MEDLINE
| ID: mdl-16445120
ABSTRACT
Predictive toxicogenomics, ie, the acquisition of advanced knowledge of the safety profile of a compound using genomic biomarkers, is a technology that provides much optimism for improving early drug discovery decisions. Toxicogenomics creates an opportunity to shift attrition to earlier stages in drug development to a point where course-corrective action can be taken with relatively lower financial costs, thus improving the efficiency of the drug development process. This review will survey the current state-of-the-art in toxicogenomics for predicting toxicity, both in vivo and in vitro, with emphasis on the use of classification algorithms and the importance of toxicogenomic databases for biomarker discovery and validation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Testes de Toxicidade
/
Toxicogenética
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article